[16]
Goode, E.L.; Chenevix-Trench, G.; Song, H.; Ramus, S.J.; Notaridou, M.; Lawrenson, K.; Widschwendter, M.; Vierkant, R.A.; Larson, M.C.; Kjaer, S.K.; Birrer, M.J.; Berchuck, A.; Schildkraut, J.; Tomlinson, I.; Kiemeney, L.A.; Cook, L.S.; Gronwald, J.; Garcia-Closas, M.; Gore, M.E.; Campbell, I.; Whittemore, A.S.; Sutphen, R.; Phelan, C.; Anton-Culver, H.; Pearce, C.L.; Lambrechts, D.; Rossing, M.A.; Chang-Claude, J.; Moysich, K.B.; Goodman, M.T.; Dörk, T.; Nevanlinna, H.; Ness, R.B.; Rafnar, T.; Hogdall, C.; Hogdall, E.; Fridley, B.L.; Cunningham, J.M.; Sieh, W.; McGuire, V.; Godwin, A.K.; Cramer, D.W.; Hernandez, D.; Levine, D.; Lu, K.; Iversen, E.S.; Palmieri, R.T.; Houlston, R.; van Altena, A.M.; Aben, K.K.; Massuger, L.F.; Brooks-Wilson, A.; Kelemen, L.E.; Le, N.D.; Jakubowska, A.; Lubinski, J.; Medrek, K.; Stafford, A.; Easton, D.F.; Tyrer, J.; Bolton, K.L.; Harrington, P.; Eccles, D.; Chen, A.; Molina, A.N.; Davila, B.N.; Arango, H.; Tsai, Y.Y.; Chen, Z.; Risch, H.A.; McLaughlin, J.; Narod, S.A.; Ziogas, A.; Brewster, W.; Gentry-Maharaj, A.; Menon, U.; Wu, A.H.; Stram, D.O.; Pike, M.C.; Beesley, J.; Webb, P.M.; Chen, X.; Ekici, A.B.; Thiel, F.C.; Beckmann, M.W.; Yang, H.; Wentzensen, N.; Lissowska, J.; Fasching, P.A.; Despierre, E.; Amant, F.; Vergote, I.; Doherty, J.; Hein, R.; Wang-Gohrke, S.; Lurie, G.; Carney, M.E.; Thompson, P.J.; Runnebaum, I.; Hillemanns, P.; Dürst, M.; Antonenkova, N.; Bogdanova, N.; Leminen, A.; Butzow, R.; Heikkinen, T.; Stefansson, K.; Sulem, P.; Besenbacher, S.; Sellers, T.A.; Gayther, S.A.; Pharoah, P.D. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Nat. Genet., 2010,
42(10), 874-879.[
http://dx.doi.org/10.1038/ng.668] [PMID:
20852632]
[66]
Kath, J.C.; Luzzio, M.J. Pyrimidine derivatives for the treatment of abnormal cell growth their preparation and pharmaceutical compositions. Pfizer Inc. USA. WO2005111016, 2005.
[67]
Kath, J.C.; Luzzio, M.J. Preparation of diamino pyrimidines for the treatment of abnormal cell growth. Pfizer Inc. USA. US 20050256144, 2005.
[68]
Kath, J.C.; Luzzio, M.J. Preparation of pyrimidine derivatives for the treatment of abnormal cell growth USA. Pfizer Inc., US 20050256145, 2005.
[69]
Holmes, I.P.; Bergman, Y.; Lunniss, G.E.; Nikac, M.; Chol, N.; Hemley, C.F.; Walker, S.R.; Foitzik, R.C.; Ganame, D.; Lessene, R. Preparation of N-phenylpyrimidin-2-amines as selective Fak inhibitors. Cancer Ther. CRC US 20130022594, 2013.
[70]
Holmes, I.P.; Bergman, Y.; Lunniss, G.E.; Nikac, M.; Choi, N.; Hemley, C.F.; Walker, S.R.; Foitzik, R.C.; Ganame, D.; Lessene, R. Selective Fak inhibitors. Cancer Ther. CRC US 20130324546, 2015.
[71]
Schlaepfer, D. Method of promoting apoptosis and inhibiting cancer metastasis by administration focal adhesion kinase (FAK) inhibitor. Poniard Pharmac., Inc. USA. WO 2011019943, 2011.
[72]
Cance, W.G.; Pandey, R.K.; Kurenova, E.V.; Ethirajan, M. Kinase protein binding inhibitors. Health Research, Inc. USA. US 20150051245, 2015.
[73]
Cance, W.G.; Pandey, R.K.; Kurenova, E.V.; Ethirajan, M. Preparation of dimethylpyridinylalkyldiamine derivatives and analogs for use as kinase protein binding inhibitors. Roswell Park Cancer Institute, USA. WO 2013074517, 2013.
[74]
Lee, J.; Song, H.J.; Koh, J.S.; Lee, H.K.; Kim, Y.; Chang, S.; Kim, H.W.; Lim, S.H.; Choi, J.S.; Kim, J.H.; Kim, S.W. Preparation of kinase inhibitors for pharmaceutical applications. Genosco, Oscotec Inc., USA. WO 2011060295, 2011.
[75]
Lafrance, L.V.; Leber, J.D.; Li, M.; Verma, S.K. Preparation of benzimidazolecarboxamides as inhibitors of FAK for treatment of proliferative diseases. GlaxoSmithKline LLC, USA. WO 2010126922, 2010.
[76]
Chu, S.S.; Alegria, L.A.; Bender, S.L; Benedict, S. P.; Borchardt, A.J.; Kania, R.S.; Nambu, M.D.; Tempczyk-Russell, A.M.; Sarshar, S. Preparation of diaminothiazoles for inhibiting protein kinases. Agouron Pharmaceuticals, Inc., USA. Patent: WO 2000075120, 2000.
[77]
Van Camp, J.; Patel, J.R.; Swann, S. Preparation of benzodiazepinones as Fak kinase inhibitors for treatment of cancers. Abbott Laboratories, USA. WO 2012045194, 2012.
[78]
Alaoui-Jamali, M.A.; Bijian, K.; Tao, J. Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof. The Royal Institution for the Advancement of Learning/Mcgill University Can. and Ocean University of China., WO 2013059927, 2013.
[79]
Yin, Y.; Su, Y. Dithiocarbamates compounds serving as fak inhibitors. Beijing Xibo Pharmaceutical Research Co. CN 111072571, 2018.
[80]
Feger, D.; Klotzbuecher, A.; Kubbutat, M.; Horst, G.; Lingnau, A.; Schaechtele, C.; Totzke, F. Use of indolocarbazole imides as selective protein kinase inhibitors for treatment of hematological and solid tumors. KTB Tumorforschungsgesellschaft m.b.H., Germany., WO 2009047216, 2009.
[81]
Breslin, H. J.; Dorsey, B.; Gregory, R. Macrocyclic compounds as ALK, Fak and Jak2 inhibitors and their preparation and use for the treatment of ALK-Fak- and Jak2-mediated diseases. Cephalon, Inc., USA. WO 2012125603, 2012.
[82]
Adams, J.L.; Faitg, T.H.; Johnson, N.W.; Peng, X. Anilinopyridines as inhibitors of Fak. SmithKline Beecham Corporation, USA. WO 2009105498, 2009.
[83]
Harling, J.D.; Tinworth, C. Compounds for treating disorders associated with aberrant kinase activity by degrading said kinase. GlaxoSmithKline, UK. WO 2018033556, 2018.
[88]
Luzzio, M. J.; Autry, C. L.; Bhattacharya, S. K.; Freeman-Cook, K.D.; Hayward, M. M.; Hulford, C. A.; Nelson, K. L.; Xiao, J.; Zhao, X. Preparation of sulfonyl amide derivatives for the treatment of abnormal cell growth. Pfizer Products Inc., USA. WO 2008129380, 2008.
[89]
Du, W.; Li, Y. Deuterated Defactinib compound and application. Hinova Pharmaceuticals Inc., Rep. China. WO 2019214587, 2019.
[117]
Gütschow, M.; Eynde, J.J.V.; Jampilek, J.; Kang, C.; Mangoni, A.A.; Fossa, P.; Karaman, R.; Trabocchi, A.; Scott, P.J.H.; Reynisson, J.; Rapposelli, S.; Galdiero, S.; Winum, J.Y.; Brullo, C.; Prokai-Tatrai, K.; Sharma, A.K.; Schapira, M.; Azuma, Y.T.; Cerchia, L.; Spetea, M.; Torri, G.; Collina, S.; Geronikaki, A.; García-Sosa, A.T.; Vasconcelos, M.H.; Sousa, M.E.; Kosalec, I.; Tuccinardi, T.; Duarte, I.F.; Salvador, J.A.R.; Bertinaria, M.; Pellecchia, M.; Amato, J.; Rastelli, G.; Gomes, P.A.C.; Guedes, R.C.; Sabatier, J.M.; Estévez-Braun, A.; Pagano, B.; Mangani, S.; Ragno, R.; Kokotos, G.; Brindisi, M.; González, F.V.; Borges, F.; Miloso, M.; Rautio, J.; Muñoz-Torrero, D. Breakthroughs in medicinal chemistry: new targets and mechanisms, new drugs, new hopes-7.
Molecules, 2020,
25(13), 2968.[
http://dx.doi.org/10.3390/molecules25132968] [PMID:
32605268]